Gilead Teases Big Cancer Drug Readouts In Second Half
The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.
You may also be interested in...
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.
Pfizer will gain two clinical-stage immuno-oncology assets targeting the SRRPα-CD47 axis that it hopes could reach the market in the 2025-2030 timeframe.
HIV PrEP and treatments saw increases in sales, though the US treatment market’s recovery was slower than expected and may need “several” quarters to return to pre-pandemic levels.